Subscribe to RSS
Clinical Outcome in Patients with Large Sinonasal Tumors with Intracranial Extension
Objectives Malignant tumors of the sinonasal cavities with extension to the frontal skull base are rare and challenging pathologies. Combined-approach surgery using a frontobasal craniotomy and endoscopic sinus surgery with reconstruction of the anterior skull base followed by adjuvant radiotherapy is a preferred treatment strategy in selected cases. Morbidity and mortality rates are high in this population. We aim to add our experience to the current literature.
Design We performed a retrospective cross-sectional single center study of the long-term clinical outcome in a tertiary university referral hospital in the Netherlands between 2010 and 2021. Descriptive statistics and frequency distributions were performed
Participants Patient, tumor, treatment, complications and survival characteristics of eighteen consecutive patients were extracted from the electronic health records.
Main Outcome Measures The primary outcome measures are progression free survival, overall survival and complication rate.
Results Eighteen consecutive patients were included with a mean age of 61 (SD ± 10) years (range 38-80); ten males and eight females. Gross total resection was achieved in 14 (77%) patients. Eleven (61%) patients underwent local radiotherapy, one (5%) chemotherapy and three (17%) a combination of both. Mean follow-up duration was 49 months (range 3 – 138). Three (17%) patients died in hospital due to post-operative complications. Six (33%) patients died during follow-up due to disease progression. Mean progression-free survival was 47 months (range 0 – 113).
Conclusion In conclusion, the overall survival was 50% for this group of patients with large sinonasal tumors. Progressive disease affects survival rate severely. Surgical complications were seen in five (28%) patients. Radiotherapy is associated with high complication rates. Radiation necrosis was a serious complication in two patients and could be treated with high dose steroids.
KeywordsSkull base - esthesioneuroblastoma - sinonasal carcinoma - inverted papilloma - squamous cell carcinoma - adenoid cystic carcinoma - radiotherapy - reconstruction - craniotomy
Received: 02 December 2022
Accepted: 24 April 2023
Accepted Manuscript online:
27 April 2023
Article published online:
24 May 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck 2012; 34 (06) 877-885
- 2 Kaplan DJ, Kim JH, Wang E, Snyderman C. Prognostic indicators for salvage surgery of recurrent sinonasal malignancy. Otolaryngol Head Neck Surg 2016; 154 (01) 104-112
- 3 López F, Lund VJ, Suárez C. et al. The impact of histologic phenotype in the treatment of sinonasal cancer. Adv Ther 2017; 34 (10) 2181-2198
- 4 Mendenhall WM, Amdur RJ, Morris CG. et al. Carcinoma of the nasal cavity and paranasal sinuses. Laryngoscope 2009; 119 (05) 899-906
- 5 Komotar RJ, Starke RM, Raper DMS, Anand VK, Schwartz TH. Endoscopic endonasal compared with anterior craniofacial and combined cranionasal resection of esthesioneuroblastomas. World Neurosurg 2013; 80 (1-2): 148-159
- 6 Hanna E, DeMonte F, Ibrahim S, Roberts D, Levine N, Kupferman M. Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol Head Neck Surg 2009; 135 (12) 1219-1224
- 7 Guntinas-Lichius O, Kreppel MP, Stuetzer H, Semrau R, Eckel HE, Mueller RP. Single modality and multimodality treatment of nasal and paranasal sinuses cancer: a single institution experience of 229 patients. Eur J Surg Oncol 2007; 33 (02) 222-228 (EJSO)
- 8 Thorup C, Sebbesen L, Danø H. et al. Carcinoma of the nasal cavity and paranasal sinuses in Denmark 1995-2004. Acta Oncol 2010; 49 (03) 389-394
- 9 Dirix P, Nuyts S, Geussens Y. et al. Malignancies of the nasal cavity and paranasal sinuses: long-term outcome with conventional or three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2007; 69 (04) 1042-1050
- 10 Hoppe BS, Stegman LD, Zelefsky MJ. et al. Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting—the MSKCC experience. Int J Radiat Oncol Biol Phys 2007; 67 (03) 691-702
- 11 Allen MW, Schwartz DL, Rana V. et al. Long-term radiotherapy outcomes for nasal cavity and septal cancers. Int J Radiat Oncol Biol Phys 2008; 71 (02) 401-406
- 12 Chen AM, Daly ME, Bucci MK. et al. Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement?. Int J Radiat Oncol Biol Phys 2007; 69 (01) 141-147
- 13 Hoppe BS, Wolden SL, Zelefsky MJ. et al. Postoperative intensity-modulated radiation therapy for cancers of the paranasal sinuses, nasal cavity, and lacrimal glands: technique, early outcomes, and toxicity. Head Neck 2008; 30 (07) 925-932
- 14 Batth SS, Sreeraman R, Dienes E. et al. Clinical-dosimetric relationship between lacrimal gland dose and ocular toxicity after intensity-modulated radiotherapy for sinonasal tumours. Br J Radiol 2013; 86 (1032): 20130459
- 15 Licitra L, Resteghini C, Bossi P. The evolving role of systemic therapy in the primary treatment of sinonasal cancer. Adv Otorhinolaryngol 2020; 84: 78-86
- 16 Haerle SK, Gullane PJ, Witterick IJ, Zweifel C, Gentili F. Sinonasal carcinomas: epidemiology, pathology, and management. Neurosurg Clin N Am 2013; 24 (01) 39-49
- 17 Taylor MA, Saba NF. Cancer of the paranasal sinuses. Hematol Oncol Clin North Am 2021; 35 (05) 949-962
- 18 Ganly I, Patel SG, Singh B. et al. Complications of craniofacial resection for malignant tumors of the skull base: report of an International Collaborative Study. Head Neck 2005; 27 (06) 445-451
- 19 Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE—Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 2021; 112 (01) 90-92
- 20 Mehta GU, Passer JZ, Raza SM. et al. The neurosurgical management of sinonasal malignancies involving the anterior skull base: a 28-year experience at The MD Anderson Cancer Center. J Neurosurg 2021; (e-pub ahead of print) DOI: 10.3171/2021.5.JNS21772.
- 21 Xu CC, Dziegielewski PT, McGaw WT, Seikaly H. Sinonasal undifferentiated carcinoma (SNUC): the Alberta experience and literature review. J Otolaryngol Head Neck Surg 2013; 42 (01) 2
- 22 Higgins TS, Thorp B, Rawlings BA, Han JK. Outcome results of endoscopic vs craniofacial resection of sinonasal malignancies: a systematic review and pooled-data analysis. Int Forum Allergy Rhinol 2011; 1 (04) 255-261
- 23 Lee MM, Vokes EE, Rosen A, Witt ME, Weichselbaum RR, Haraf DJ. Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results. Cancer J Sci Am 1999; 5 (04) 219-223
- 24 Orlandi E, Cavalieri S, Granata R. et al. Locally advanced epithelial sinonasal tumors: The impact of multimodal approach. Laryngoscope 2020; 130 (04) 857-865
- 25 Bossi P, Saba NF, Vermorken JB. et al. The role of systemic therapy in the management of sinonasal cancer: a critical review. Cancer Treat Rev 2015; 41 (10) 836-843